{"id":203464,"date":"2025-12-26T00:00:00","date_gmt":"2025-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/47037405-medtech-transcatheter-embolization-and-occlusion-devices\/"},"modified":"2026-03-31T10:09:11","modified_gmt":"2026-03-31T10:09:11","slug":"47042553-medtech-transcatheter-embolization-and-occlusion-devices-market-insights-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042553-medtech-transcatheter-embolization-and-occlusion-devices-market-insights-asia-pacific\/","title":{"rendered":"Transcatheter Embolization and Occlusion Devices – Market Insights – Asia Pacific"},"content":{"rendered":"

The Asia Pacific TEO<\/abbr> device market will experience steady growth over the forecast period, driven by rising cancer incidence, increasing preference for minimally invasive procedures, and clinical evidence supporting embolization and flow-diversion technologies. Neurovascular flow-diverting devices will see the fastest adoption, while emerging indications such as chronic subdural hematoma will further expand procedural volumes. Pricing reforms, including VBP<\/abbr> in China, will exert downward pressure on ASP<\/abbr>s and alter competitive dynamics; however, higher procedure volumes and continued uptake of innovative devices will sustain moderate revenue growth across the region.<\/p>\n

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for TEO<\/abbr> devices in the Asia Pacific region from 2019 through 2034.<\/p>\n

New evidence supporting the use of embolization devices for treating chronic subdural hematoma, in addition to their existing use for tumor indications, will drive growth in neurovascular embolization procedure volumes.<\/strong><\/p>\n

Which embolization devices will see the strongest adoption in the treatment of chronic subdural hematoma?<\/p>\n

How will the increasing use of embolization devices for tumor and hyperplasia indications impact overall neurovascular embolization procedure volumes in Asia Pacific region?<\/p>\n

Which tumor types are driving the highest procedural growth in embolization procedures?<\/p>\n

How will the uptake of embolization procedures in the treatment of chronic subdural hematoma vary across the Asia Pacific region?<\/p>\n

Which companies will see market share gains?<\/p>\n

Flow-diverting devices are contributing to growth in the Asia Pacific TEO<\/abbr> device market.<\/strong><\/p>\n

How will the adoption of flow-diverting devices impact the neurovascular embolization coil and coiling-assist device markets?<\/p>\n

Which strategies are competitors adopting to gain a competitive edge over other competitors in the flow-diverting device market?<\/p>\n

What will be the impact of emergence of new competitors and products in the Asia Pacific TEO<\/abbr> device market?<\/p>\n

Liquid embolics are gaining traction in Asia Pacific region due to their versatility in treating aneurysms, cSDH, and peripheral conditions like hemorrhage and tumors.<\/strong><\/p>\n

How will the growing adoption of liquid embolics for cSDH and aneurysm treatment impact overall neurovascular procedure volumes in Asia Pacific?<\/p>\n

How will portfolio breadth and clinical evidence influence competitive positioning in the liquid embolic segment?<\/p>\n

Positive clinical data will play a key role in driving the adoption of embolization devices, especially the premium-priced devices such as radioembolization spheres and DEB<\/abbr>s.<\/strong><\/p>\n

Which clinical trials were recently conducted in this market?<\/p>\n

What is the expected impact of these clinical trials on market dynamics?<\/p>\n

Reimbursement will be a crucial factor in the adoption of embolization procedures in the cost-conscious Asia Pacific region.<\/strong><\/p>\n

What is the reimbursement scenario in the Asia Pacific region?<\/p>\n

How will reimbursement availability impact the TEO<\/abbr> device market in future?<\/p>\n

How is the use of premium embolization consumables being influenced by the reimbursement changes in Australia and South Korea?<\/p>\n

What impact does cost sensitivity have on hospitals’ and doctors’ preferences for local versus foreign equipment vendors in emerging markets?<\/p>\n

China\u2019s centralized procurement measures will impact the overall TEO<\/abbr> device market.<\/strong><\/p>\n

What are the major changes in the ASP<\/abbr>s of various embolization and accessory devices after the implementation of VBP<\/abbr>?<\/p>\n

How has the market shifted due to bulk volume procurement following VBP<\/abbr> implementation for TEO<\/abbr> devices?<\/p>\n","protected":false},"template":"","class_list":["post-203464","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-cardiovascular","medtech-therapy-area-transcatheter-embolization-and-occlusion-devices","medtech-geography-asia-pacific","medtech-date-2294"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/203464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":8,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/203464\/revisions"}],"predecessor-version":[{"id":572094,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/203464\/revisions\/572094"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=203464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}